Fig. 2

a) Table showing the significance of the intersections of upregulated and downregulated genes between ASD and the 22 cancer types included in our study, comprising, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), bladder cancer (BLAD), brain cancer (BRAIN), breast cancer (BREAST), cervical cancer (CERVI), cholangiocarcinoma (CHOL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), colorectal cancer (CRC), diffuse large b cell lymphoma (DLBCL), follicular lymphoma (FLYMPH), gastric cancer (GSTCA), head and neck carcinoma (HNC), kidney cancer (KIDN), liver cancer (LIV), lung cancer (LUNG), melanoma (MEL), ovarian cancer (OV), pancreatic cancer (PANC), prostate cancer (PROST), and thyroid cancer (THYR). Columns A, B, C, and D include the number of genes upregulated in both, downregulated in both, upregulated in ASD and downregulated in cancer, and downregulated in ASD and upregulated in cancer, respectively. Green cell colors indicate significant intersections (FDR corrected p-values from Fisher’s exact test lower than 0.05) with darker green tones indicating lower FDR corrected p-values. b) Venn diagrams showing the number of genes commonly deregulated in SDDCs and ODDCs. c) Scatter plots and correlation values, depicting the associations between ASD and all SDDC and ODDCs for cancer differential expression profiles. d) Heatmap showing the differential expression status of genes included in the KEGG hsa04151 pathways (PI3K-Akt signaling pathway), that were found to be differentially expressed in the ASD differential expression meta-analyses. White, gray and black cells indicate unaltered, downregulated and upregulated differential expression status, respectively